Key Inclusion Criteria:

          -  Up to 5 prior regimens for MCL. Prior therapy must have included anthracycline- or
             bendamustine-containing chemotherapy and anti-CD20 monoclonal antibody therapy.
             Individuals must not have received prior therapy with a BTKi.

          -  At least 1 measurable lesion

          -  Platelet count ≥ 75,000/uL

          -  Creatinine clearance (as estimated by Cockcroft Gault) ≥ to 60 cc/min

          -  Cardiac ejection fraction ≥ 50%, no evidence of pericardial effusion as determined by
             an echocardiogram (ECHO), and no clinically significant electrocardiogram (ECG)
             findings

          -  Baseline oxygen saturation > 92% on room air

        Key Exclusion Criteria:

          -  Known history of infection with human immunodeficiency virus (HIV) or hepatitis B
             (HBsAG positive) or hepatitis C virus (anti-HCV positive). Individuals with a history
             of hepatitis infection must have cleared their infection as determined by standard
             serological and genetic testing

          -  History of a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia,
             cerebellar disease, cerebral edema, posterior reversible encephalopathy syndrome, or
             any autoimmune disease with central nervous system (CNS) involvement

          -  Presence of fungal, bacterial, viral, or other infection that is uncontrolled or
             requiring IV antimicrobials for management

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.